Statement by Prime Minister Carney on National Acadian Day

“Today, we celebrate National Acadian Day and honour the courage and resilience of the Acadian people, who have defended their language, culture, and identity for centuries. From Caraquet to Chéticamp, from Bonaventure to Tignish, Acadians have helped shape our country's collective identity. Canada's new government is committed to preserving this heritage- by investing in celebrations […]

VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs Hoffmann-La Roche Limited (Roche Canada) is pleased to announce today that VABYSMO® (faricimab injection) is now publicly funded for macular edema secondary to retinal vein occlusion (RVO) on the Régie de l'assurance maladie du

Opendoor Announces CEO Search in Support of Next Phase of Growth and Innovation

Opendoor Announces CEO Search in Support of Next Phase of Growth and Innovation Shrisha Radhakrishna appointed as President and interim leader of Opendoor GlobeNewswire August 15, 2025 SAN FRANCISCO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Opendoor Technologies Inc. (Nasdaq: OPEN), a leading e-commerce platform for residential real estate transactions, today announced that effective immediately, the

Cycurion, Inc. Offers Insight on Second Quarter 2025 Results and Recent Business Activities

(NasdaqGM:CYCU),(NASDAQ:CYCUW), MCLEAN, Va., Aug. 15, 2025 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a premier cybersecurity and IT solutions provider, following the release of its second-quarter financial results highlighting a period of strategic integration and debt reduction amid one-time expenses, will be conducting a business update on Tuesday, August 19, 2025

Turtle Beach Corporation, Together With The Donerail Group, Announces $20 Million Share Repurchase From Shareholder

(NasdaqGM:TBCH), SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Turtle Beach Corporation (Nasdaq: TBCH, the “Company”), a leading gaming accessories brand, today announced it entered into a definitive agreement to repurchase 694,926 shares of common stock from Diversis Capital (“Diversis”), at the 30-day volume weighted average price of $14.41 per share, for a total of

Faraday Future Reminds the Public That it Will Announce a Major Strategy Upgrade With its Dual-Flywheel & Dual-Bridge Eco Strategy on August 16th, at Pebble Beach

(NASDAQ:FFAI), FF wraps up its 5-day countdown today, leading up to the August 16 announcement. The 5 teasers each uniquely defined specific components of the Company's new strategy and will unveil respective updates. LOS ANGELES, Aug. 15, 2025 (GLOBE NEWSWIRE) — Faraday Future Intelligent Electric Inc. (NASDAQ: FFAI) (“Faraday Future”, “FF” or the “Company”), a

SAGTEC to Drive Cutting-Edge F&B Technology Transformation for Malaya Heritage

(NASDAQ:SAGT), KUALA LUMPUR, Malaysia, Aug. 15, 2025 (GLOBE NEWSWIRE) — Malaya Heritage Holding Limited, the holding company for CNS Food Centre Sdn Bhd, has appointed SAGTEC Global Limited (“SAGTEC”) as its exclusive IT Consultant to lead a comprehensive 24-month digital transformation program across its F&B operations. The partnership will introduce advanced technologies including automated central

Your Pump Is Trying to Tell You: You Need a Better Nursing Bra

New York, NY, Aug. 15, 2025 (GLOBE NEWSWIRE) — Most moms begin their breastfeeding journey with a pump and a bra, often purchased separately. Both may seem like smart choices, but when used together, they often don't align. Hands-free turns into hands-on. Leaks happen. Comfort disappears. Instead of gaining time and freedom, moms are stuck

Regen BioPharma Discusses Potential Impact of HemaXellerate on Chemotherapy Treament Market

(Other OTC:RGBP),(OTC US:RGBP),(OTC US:RGBPP),(Other OTC:RGBPP), SAN DIEGO, Aug. 15, 2025 (GLOBE NEWSWIRE) — Regen BioPharma, Inc. (OTC ID: RGBP and RGBPP) today provided further insight into its planned Phase 1 clinical trial of HemaXellerate, the company's innovative stem cell-derived therapy, which has already received U.S. FDA clearance. While the initial focus is on treating aplastic

Scroll to Top